Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD)

HIV Medicine

Volumn 11, Issue 8, 2010, Pages 519-529

  Oyomopito, R ^a,b   Lee, M P ^c   Phanuphak, P ^d   Lim, P L ^e   Ditangco, R ^f   Zhou, J ^a   Sirisanthana, T ^g   Chen, Y M A ^h   Pujari, S ⁱ   Kumarasamy, N ^j   Sungkanuparph, S ^k   Lee, C K C ^l   Kamarulzaman, A ^m   Oka, S ⁿ   Zhang, F J ^o   Mean, C V ^p   Merati, T ^q   Tau, G ^r   Smith, J ^s   Li, P C K ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^e TAN TOCK SENG HOSPITAL   (Singapore)

^f RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^g Research Institute for Health Sciences   (Thailand)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ Institute of Infectious Diseases   (India)

^j YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^k MAHIDOL UNIVERSITY   (Thailand)

^l HOSPITAL SUNGAI BULOH   (Malaysia)

^m UNIVERSITY OF MALAYA   (Malaysia)

ⁿ NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^o CAPITAL MEDICAL UNIVERSITY   (China)

^p National Center for HIV/AIDS   (Cambodia)

^q UDAYANA UNIVERSITY   (Indonesia)

^r PORT MORESBY GENERAL HOSPITAL   (Papua New Guinea)

^s Foundation for AIDS Research   (United States)

more..

Author keywords

Antiretroviral therapy; Asia; CD4 counts; Diagnostic monitoring; Viral load

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG USE; ECONOMIC ASPECT; EXPOSURE; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCOME; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INCOME; MALE; MODELS, STATISTICAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 77955252840     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00822.x     Document Type: Article

References (36)

1. Robbins GK, De Gruttola V, Shafer RW. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003, 349:2293-2303.
2. Shafer RW, Smeaton LM, Robbins GK. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003, 349:2304-2315.
3. http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2006/default.asp, UNAIDS., AIDS epidemic update: special report on HIV/AIDS, 2006, Available at
4. Egger M, Boulle A, Schechter M, Miotti P. Antiretroviral therapy in resource-poor settings: scaling up inequalities? Int J Epidemiol 2005, 34:509-512.
5. Zhou J, Kumarasamy N, Ditangco R. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005, 38:174-179.
6. Sow PS, Otieno LF, Bissagnene E. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. J Acquir Immune Defic Syndr 2007, 44:262-267.
7. Hughes MD. Evaluating surrogate endpoints. Controlled Clin Trials 2002, 23:703-707.
8. Mellors JW, Munoz A, Giorgi JV. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
9. Hammer SM, Saag MS, Schechter M. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006, 296:827-843.
10. Hughes MD, Johnson VA, Hirsch MS. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 protocol virology substudy team. Ann Intern Med 1997, 126:929-938.
11. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008, 1-128. http://www.aidsinfo.nih.gov, Available at, (accessed 21 April 2008)
12. Guidelines for the clinical management and treatment of HIV infected adults in Europe. http://www.europeanaidsclinicalsociety.org, European AIDS Clinical Society (EACS)., Available at, (accessed 21 April 2008)
13. Cohen GM. Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries. AIDS 2007, 21((Suppl. 4)):S81-S87.
14. Freedberg KA, Losina E, Weinstein MC. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001, 344:824-831.
15. Goldie SJ, Yazdanpanah Y, Losina E. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d'Ivoire. N Engl J Med 2006, 355:1141-1153.
16. Fiscus SA, Cheng B, Crowe SM. HIV-1 viral load assays for resource-limited settings. PLoS Med 2006, 3:e417. doi, 10.1371/journal.pmed.0030417
17. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 41:1-19. CDC.
18. http://go.worldbank.org/K2CKM78CC0, World Bank., World Bank list of economies, Available at, (accessed July 2007)
19. Egger M, May M, Chene G. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
20. Braitstein P, Brinkhof MW, Dabis F. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
21. Braitstein P, Zala C, Yip B. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 2006, 193:259-268.
22. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 33:365-372.
23. Greub G, Ledergerber B, Battegay M. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
24. Bosch RJ, Bennett K, Collier AC, Zackin RB. Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 44:268-277.
25. Mocroft A, Phillips AN, Gatell J. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007, 370:407-413.
26. Lange CG, Lederman MM, Medvik K. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2015-2023.
27. Wu H, Connick E, Kuritzkes DR. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001, 17:1231-1240.
28. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006, 6:-59.
29. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA 2000, 284:223-228.
30. http://www.un.org/ga/president/62/issues/hiv/A-62-780.pdf, United Nations General Assembly., Declaration of Commitment on HIV/AIDS and Political Declaration on HIV/AIDS: midway to the Millennium Development Goals, 2008, Available at, (accessed 18 May 2008)
31. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008, 371:1443-1451.
32. Cozzi-Lepri A, Phillips AN, Ruiz L. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007, 21:721-732.
33. Kumarasamy N, Madhavan V, Venkatesh KK. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 2009, 49:306-309.
34. http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf, World Health Organisation., Towards universal access: scaling up priority HIV/AIDS interventions in the health sector, 2008, Available at, (accessed 2 July 2008)
35. http://www.who.int/bct, World Health Organisation., Technical Working Group for the development of an HIV/AIDS diagnostic support toolkit, 2002. Available at, (accessed 23 January 2009)
36. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008, 13((Suppl. 2)):1-13.